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The development of early and personalized diagnostic protocols is considered the most promising avenue to
decrease mortality from cancer and improve outcome. The emerging microfluidic-based analyzing platforms hold
high promises to fulfill high-throughput and high-precision screening with reduced equipment cost and low
analysis time, as compared to traditional bulky counterparts in bench-top laboratories. This article overviewed the
potential applications of microfluidic technologies for detection and monitoring of cancer through nucleic acid and
protein biomarker analysis. The implications of the technologies in cancer cytology that can provide functional
personalized diagnosis were highlighted. Finally, the future niches for using microfluidic-based systems in tumor
screening were briefly discussed.
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Although much progress has been made in the diagnosis
and treatment of malignancy, cancer is still the most
common cause of death worldwide. Most patients with
cancer have symptoms and distant metastases when di-
agnosed, which makes it more difficult to successfully
treat the disease. Therefore, accurate prediction and diag-
nosis at early time are the most critical issues in cancers.
Recently, significant efforts have been put into finding in-
formative cancer biomarkers that can contribute to the es-
tablishment of cancer diagnosis [1]. The biomarkers
encompass mutated DNAs and RNAs, secreted proteins,
and tumor cells (e.g., circulating tumor cells, tumor stem
cells) [1]. Ideally, the measurements of cancer biomarker
screening are supposed to be done at high accuracy with
automation and cheaply at point-of-care to reduce costs.
Unfortunately, the methods performed typically in trad-
itional bench-top laboratories are usually not amenable to
high-throughput screening which are responsible for
large-scale “-omics” studies and have been approaching a
plateau in almost all fields of oncology. In the past de-
cades, vigorous efforts have been undertaken to develop
new and robust laboratory tests. Gained from the* Correspondence: wqdmu@yahoo.com.cn
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reproduction in any medium, provided the oradvances of micro- and nano-fabrication approaches,
microfluidic technologies, also referred to as Lab-on-a-
Chip (LOC) or micro-total analysis systems (μTAS),
offer tremendous hope in both point-of-care cancer bio-
marker measurements and personalized diagnostic
strategies and have evolved state-of-the-art devices for
cancer research [2,3].
Typically, microfluidic technologies enable the actuation
of fluids and manipulation of bioparticles (e.g. DNA,
RNA, proteins, and cells) at the microscale [4]. Fluid flow
in ultralow dimensions of micrometers is laminar and can
be precisely controlled by adjusting the flow rate. The dis-
tinct property gives rise to more efficient and accurate
mass delivery to cancer cells in controlled time and space
[5,6]. Also, because microfluidic platforms have scalable
sizes with most biological macromolecules, cells and blood
vessels, they provide unique functionality for the design
and remodeling of precise scaffolds, which mimick the
physiological tumor microenvironment [7]. The character-
istics are especially suitable for cancer cytology research
considering that cancer cells have been found to present
enhanced viability, invasion, and variable therapeutic re-
sponse when embedded in microfluidic culture systems
[8,9]. Most importantly, the microfluidic-based studies
pave the way for integrated genomic, proteomic, and
cytomic analyses to identify hundreds of novel candidate
biomarkers potentially involved in tumorigenesis [10,11].tral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1472-6750/13/76As discussed in this review, microfluidic chips are gaining
exclusively interest in the emerging field of systems oncol-
ogy. The tequniques provide new avenues to facilitate the
thorough understanding of the molecular mechanisms of
malignancy at the systems-level.
This article presented a current overview about the
potential application and perspectives of microfluidic
technology in clinical oncology. Notably, due to the wide
range and rapid proliferation of the subject matter, the
paper was not intended to provide a comprehensive re-
view but to provide the reader with a practical appreci-




Genetic changes in cancer cells which lead to altered
gene expression patterns can be utilized as biomarkers
for detection and diagnosis of cancer [12]. Gene exp-
ression profiles have shown dramatic correlations with
tumor development, progression, intra- and extra-
vascular invasiveness, and patient outcome when applied
to biopsy samples. However, the profiles of somatic mu-
tations in different tumors are much more complicated
than we can imagine and the complexity of mutational
heterogeneity makes it difficult to identify key cancer
genes that could provide sufficient diagnostic utility
[12,13]. Recently, microfluidic chip based devices have
been increasingly heralded as robust techniques for gen-
omic diagnosis, holding promises to profile tumor gen-
omic sequences and interpret the implication of such
sequences in e.g. cancer origin, or progression.
The development of a high-speed, high-throughput
DNA sequencing method represented the most attractive
challenge for clinical molecular diagnostics, especially mu-
tation detection and genetic screening. Capillary array
electrophoresis (CAE) appears to be a prime candidate to
be employed among various DNA sequencing methods
[14]. Since considerable advances in microtechnology
allow smaller and denser microchannel arrays with com-
plex turn geometries to be fabricated, microfluidic-based
CAE (μCAE) chips for multiplex sequencing of oncogenes
have been at the center of scientific interest. For example,
a microfluidic gene array was used to indicate the down-
regulated gene expression profiling of mTOR-associated
tumor suppressor genes in ovarian cancer patients [15]. A
spatial temperature gradient μCAE system was presented
for quantitative detection of low-abundance mutation
DNA [16]. The system obtained accurate separation and
detection of K-ras gene from paraffin tissue sections of
colorectal cancer. Indeed, rectilinear and radial channels
for parallel high-throughput analysis have been designed
on microfluidic devices in DNA assays (Figure 1). Integrat-
ing microfluidic channels on chips provide a potential forreducing DNA diffusion time and optimizing hyb-
ridization conditions, such as temperature, ionic strength,
and denaturant concentration.
The use of microchips as a miniaturized polymerase
chain reaction (PCR) platform realizes an autonomous
lab-on-a-chip system, which can reduce the overall ana-
lysis cost as well as preventing the potential for sample
cross contamination, and importantly, provide the more
accurate and high-throughput means of cancer gene re-
search [18]. Generally, two kind of configurations are
used in PCR microfluidic devices: (1) a stationary con-
figuration as in conventional PCR wherein the sample
is held in a microchamber and the temperature of
the chamber is cycled; (2) a flow-through configuration
wherein the sample flows through different thermal
zones, which are responsible for distinctive processes,
such as denaturation, annealing and extension [2]. A
continuous-flow PCR microfluidic chip was recently de-
veloped by employing a water cooling thermocycling
within the chip center whereby the sequence of denatur-
ation, annealing, and extension was created due to the
forced convection effect and DNA fragments with differ-
ent lengths (372 bp and 478 bp) were successfully ampli-
fied [19]. More efforts also include integrating PCR with
sample preparation steps such as DNA purification. A
microfluidic sequencing enrichment method was repor-
ted for oncogene identification on a genome-scale level
[10]. In this study, a 480 Kb exome subset of 115
cancer-related genes were captured. The device also re-
vealed an analysis of reference single nucleotide poly-
morphisms (SNP) with a sensitivity of up to 93 % and a
specificity of 98.2% or higher. Due to advantages of effi-
cient sample handling and in vitro transcription reactions,
on-chip RT-PCR is also successfully applied in cancer re-
search. For example, a multiplex RT-PCR (mRT-PCR)
assay was developed for rapid screening of alterations in
prostate cancer genes at miRNA levels. This design was
characterized by its integration with microfluidic-based
on-chip electrophoresis [20]. Multiplexing made the ap-
proach superior to gene-by-gene analysis by quantitative
RT-PCR and more reliable for analyzing rare amounts of
RNA from clinical tumor biopsies. Similarly, a real-time
quantitative PCR (qPCR)-based microfluidic platform was
used to evaluate the miRNA expression levels in lung can-
cer cell lines [21]. This approach exhibited a throughput
that was 5 to 20 times higher and a sample and reagent
usage that was approximately 50-100 times lower than
conventional assays.
Microfluidic-based protein analysis
Although gene analysis has opened up a few applications
in cancer research, discrepant changes in gene expres-
sion might not be reflected accurately to the level of
protein expression or practical function [22]. Protein
Figure 1 High-throughput μCAE device. (A) Layout of the 384-channel μCAE device. (B) Expanded view of a single quartet of channels and
their injectors. The channels of a quartet share a common cathode reservoir. The injector was fabricated with individual sample reservoirs (S1–S4).
(Reproduced with permission from Ref [17]).
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and it in turn leverages both the gene expression and
cellular metabolism. For a better understanding of can-
cers and their refined classification at the systems-level,
the analysis of protein expression and function is of par-
ticular importance. However, the identification of pro-
teins expressed in a given sample has presented unique
analytical challenges, including significant molecular di-
versity, dynamic range of proteins at the cellular level,
extreme complexity of post-translational modifications
and a tendency to adsorb to solid surfaces [23]. Herein,
we focused on microfluidic screening of biomarker pro-
teins that can be used not only for indicating the onset,
progression and invasion of cancer but for directing per-
sonalized cancer diagnosis and treatment monitoring.
Integrated CAE microchips have potential to address
needs in high-throughput assays of proteins, in parti-
cular, capturing and quantifying cancer biomarkers. Apolymethyl methacrylate (PMMA) microchip CAE sys-
tem was fabricated with integrated on-chip fluorescence
derivatization function [24]. The device consisted of 8
parallel lanes, allowing up to 8 different samples to be
labeled and separated simultaneously. The system was
demonstrated to be capable of separating a cancer-
related protein from the mixtures of model biomarkers
in parallel (Figure 2). Recently, a microfluidic chip was
reported to realize miniaturized Western blotting for
protein assay. The device was interfaced to a moving
membrane so that protein complexes were separated by
sieving electrophoresis in discrete zones as they migrate
from the chip. Capture of proteins were completed in
2 min with 4 × 104 theoretical plates at 460 V/cm. Total
analysis time including immunoassay was nearly half
an hour for a single sample. Further improvements in
throughput could be aquired by increasing more sample
reservoirs or parallel channels on the chip [25].
Figure 2 Schematic of the integrated microchip CAE device. (A) the bottom layer; (B) the top layer; (C) a complete device. Reservoirs 1-8 are
sample inlets and reservoir 9 is the fluorescent label inlet. All parallel electrophoresis units share the same electrophoresis reservoirs (reservoirs
10-12: buffer inlet, buffer waste, and separation waste). (Reproduced with permission from Ref [24]).
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methods rely on qualitative tissue immunohistochemistry
(IHC). IHC allows the identification of proteins of interest
and provides information on protein localization and tis-
sue morphology. However, it is now apparent that panels
of protein cancer biomarkers, as opposed to single bio-
markers, will be necessary for reliable cancer detection
and monitoring [26]. Unfortunately, multiparametric ana-
lyses via conventional IHC are technologically challenging
and rarely used clinically. Although co-expression for bio-
markers was realized by direct and indirect sequential
staining methods with molecular dyes and quantum dots,
multicolor IHC studies suffered several drawbacks, includ-
ing low stability of primary antibodies, difficult conju-
gation of probe to antibodies, high cost of reagents, and
cross-over nonspecific binding of secondary probes [27].
Microfluidic-based IHC platforms have been proposed as
robust quantitative tools to further enhance throughput of
cancer biomarker multiplexing [28,29]. A microfluidic
multiplexed IHC device was developed via interfacing
specimens slide with different reaction microchannels on
a chip [29]. Through this platform, several cancer-related
proteins could be simultaneously investigated on a single
tumor tissue section, which facilitated histopathological
diagnosis and individualized therapy of cancer.
Over the past century, mass spectrometry (MS) has
evolved into a primary analytical tool in the proteomics
area because of its sensitivity and accuracy. Advances in
MS have been achieved by combining with several tech-
niques, including gas and liquid chromatography, CE,
electrospray ionization (ESI) and matrix-assisted laser de-
sorption ionization (MALDI) [30,31]. The coupling of
microfluidics to multi-techniques of MS analysis hasshown more immediate promise to achieve signatures for
cancer research by addressing issues like speed, through-
put, technically complex and cost efficiency. For instance,
a chip-based, reversed-phase liquid chromatography-
MALDI-MS analysis platform was utilized for quantifica-
tion of glycomic-profile changes as cancer-biomarker
discovery [32]. Another mode integrating chip-CE to
nano-ESI MS realized higher sensitivity of the trace-level
protein biomarker detection. [33] Disposable nanospray
emitters and the chip itself as the MALDI target made the
interface more suitable for point-of-care [33]. Besides, the
innovative chip devices produced an extremely low dead
volume connection which normally has a significant im-
pact on analytic results by classic MS. An off-line coupling
microchips to MALDI, called integrated selective enrich-
ment target technology, was developed to provide faster
multiplex analysis of proteomic samples with high-
sensitivity by minimizing the number of sample transfers
and the total surface area [34].
Cancer cytology analysis with microfluidic systems
The research of cancer cytology is the most straightfor-
ward way for screening and monitoring precancer and
cancer lesions [35]. Bioanalysis at cellular level gives direct
information of a single cancer cell or cell-to-cell commu-
nication within a complex tumor microenvironment. Due
to their compatible sizes with cells, microfluidic systems
are ideal platforms for cell manipulation and analysis
in vitro.
Cell sorting
The accurate separation of tumor cell subpopulations is a
preliminary but often tedious step for cancer cell biology.
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are fluorescence-activated cell sorting (FACS) and
magnetically-activated cell sorting (MACS) [36-38]. The
technologies provide several advantages, such as rapid
single-cell level separation, enrichment and purification of
rare cells (e.g. tumor stem cells and circulating tumor
cells), and high-speed multiparameter analysis [37,39,40].
Traditional cell sorting systems, however, are still cumber-
some and costly, which limit the full utilization of these
systems in various biomedical research and clinical appli-
cations [41]. In this regard, chip-based separation formats
are especially powerful. In recent years, numerous micro-
fluidic cell sorters have been designed, which are based on
various sorting principles, including electric, magnetic,
hydrodynamic and optical mechanisms [41-44].
Significant progress has so far been made toward de-
veloping microfabricated FACS (μFACS), enabling high
screening throughput and high purity enrichment. Op-
tical force was firstly developed in a μFACS system to
sort fluorescent Hela cells [45]. The system allowed a
rapid, high efficient control of cell isolation while no sig-
nificant influence on cell viability, activation state, and
functionality occurred. Recently, a microfluidic cell sor-
ter was used for circulating tumor cell detection, on-
chip culture and subsequent analyses through cell
retrieval [46]. Also, a hydrodynamic driving μFACS was
further reported with a hydrodynamic gating valve permit-
ting automatic on-chip sorting with an average purity of
93%, a recovery rate of 93%, and a viability of 94% [47].
Notably, a fully integrated μFACS system could realize
coupling optics, acoustics and electronics system on a sin-
gle microfluidic platform (Figure 3) [41]. The device has a
main microfluidic channel followed by a sorting junctionFigure 3 A fully integrated μFACS system coupling various sorting pr
and a sorting PZT actuator. The cell trajectory plot under different voltage
photos taken by a high-speed CMOS camera. (B) Schematic of the overall
was collected by a microscope objective lens. Fluorescence signals were m
filters at the image plane and were registered by the photomultiplier tube
electronic control system for real-time processing. (Reproduced with permiand three sub-channels for collecting waste and samples.
The laser light was delivered to the device by the optical
fiber and guided by optofluidic waveguide. A piezoelectric
lead-zirconate-titanate (PZT) actuator was integrated in
the sorting junction. As the PZT actuator bent down, the
cell of interest flew to the sorting channel while the non-
targeted cell flew to the waste channel. By using the in-
novative actuation mechanisms, single cell manipulation
was achieved at a high throughput with high purification
enrichment factor. In addition, the requirement of a
low voltage (<10 V) and the low consumption of power
made it much more suitable for point-of-care diagnostic
applications.
Alternatively, many other types of microfluidic-based
sorting devices have also been proposed lately. Micro-
system based MACS technologies (μMACS) allows high-
throughput sorting of target cancer cells from the clinical
samples based on target-specific affinity markers [42,48].
Lien et al reported a three-dimensional (3D) microfluidic
platform for rapid isolation and detection of cancer cells
from a large sample volume [42]. With the incorporation
of surface-modified magnetic beads, target cancer cells
were specifically recognized and were subsequently iso-
lated and purified with a high sensitivity. This system
presented a promising platform for the analysis of tumor
genetic marker utilizing the built-in nucleic acid amplifica-
tion module. A microfluidic dielectrophoresis (DEP)-acti-
vated cell sorter was developed for the isolation of human
leukemia cells from dilute blood samples [49]. DEP has
advantages of low-voltage operation and selectivity for
driving cells by frequency. A microfluidic fluorescence-
activated droplet sorter (μFADS) was also reported [50].
In this study, single cells were encapsulated in emulsioninciples. (A) Structure of the μFACS device with microfluidic channels
magnitudes to the PZT actuator was observed with superimposing
μFACS system. The laser-induced fluorescence from the stained cells
odulated into a time-domain signal of similar waveform via a spatial
(PMT). The output signal from the PMT was imported into the
ssion from Ref [41]).
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sorting approach was expected to provide a new concept
for studies of rare phenotypes within heterogeneous popu-
lations of cells. A microfluidic surface acoustic wave actu-
ated cell sorter was patterned to isolate melanoma cells
[51]. The device represented the combined advantages of
both the FACS and FADS. In addition, it saved the trouble
of prior encapsulation into liquid droplet compartments.
Most importantly, the low shear forces of this device en-
sured that no significant damage occurred to the cells
during the sorting procedures, which allowed subsequent
applications for other bioassays. Recently, a microfluidic
acoustophoretic chip was also used to sort cancer cells
based on cell mechanical properties and cell size [52]. The
chip could produce acoustic-standing-waves under which
cancer cells with different mechanical properties show dif-
ferent transmission intensity. The acoustophoresis chip
had a straight flow channel with a piezoelectric transducer
attached at the bottom. By using the model, the trajector-
ies of cells in the channel under acoustic standing wave
excitation which showed different metastatic capacities
were calculated.
Single cell analysis
The heterogeneity of cancer cells which can dramatically
influence cell fate and biological responses has led to in-
creased interest in individual cell studies. A number of
single cell analysis approaches have been established,
among which flow cytometry and fluorescence micros-
copy are most commonly employed [53]. These methods,
however, have challenges with complexity, time and sam-
ple consumption, and most importantly, inefficiencies in
manipulating single cells in real time [53]. For the pur-
pose of achieving total single cell analysis (that is, analysis
of whole cells or cell lysates or both), the development of
high-throughput systems capable of handling and analyz-
ing individual cells is essential. In the past decade years,
microfluidics has been rapidly developed into a powerful
approach capable of integrating multiple functions for
single cell analysis [54].
Intact single-cell analysis Cancer cell populations rep-
resent intrinsically variable and stochastic systems char-
acterized by high levels of spatiotemporal complexity
[55]. However, conventional cell-based assays can only
measure the average response from a population of cells
and provide statistically meaningful data. This simplifica-
tion can lead to a misleading readout. One approach to
solve this dilemma is to analyze the whole population at
individual cell level.
Rapid analysis and characterization of primary cancer
cells using microfluidic technology has aroused many
interest for clinical research of oncology. At present,
microfluidic flow cytometry (μFCM) has offered promis-
ing avenues that leverages the multiparameter and high-speed measurements owing to their established nature.
For instance, McKenna et al reported a multi-channel par-
allel μFCM that was based on analog detection combined
with parallel microfluidics [56]. The multiple microfluidic
flow channels allowed the independent optimization of
cell count rate, samples per minute, and signal-to-noise
ratio, proving the feasibility in high content screening.
Nevertheless, μFCM still suffers from a lack of capabilities
for dynamic analysis of single living cells [53,57]. This
leads to the development of new LOC designs, that is, liv-
ing cell microfluidic arrays. These unique formats allow
creating positioned arrays to arrange the cells in a spatially
defined pattern and as such are ideal platforms for kinetic
and multivariate analysis on a single cell level, which is
particularly useful for understanding cell-to-cell variability
as well as cancer cell decision making [57]. Furthermore,
unlike static cell microarrays, microfluidic cell arrays that
allow for fabrication of parallelized and fully addressable
arrays facilitate physiologically relevant exchange of stimu-
lants and metabolites and thus attain a precise spatiotem-
poral control of cell behavior over the artificial on-chip
microenvironment (Figure 4) [58].
Alternatively, an innovative design was developed
using a miniaturized diagnostic magnetic resonance
(DMR) system for multiplexed, quantitative and rapid
analysis of cancer cells [59]. With the chip-based biosen-
sor, cancer cells were detected by targeting cell surface
markers. The resulting DMR systems were anticipated
to be a truly portable, easy-to-use and low-cost device
for point-of-care use. Subsequently, a miniaturized nu-
clear magnetic resonance probe was used for detection
and molecular profiling of cancer cells [60]. The distinct
advantage of the method was its potential for detecting
rare cancer cells in the unprocessed cancer samples in a
few minutes. Notably, miniature label-free cell analysis
systems have been used to interrogate whole cells.
Typical examples of label-free on chip cytometry were
spectral impedance measurements which provided infor-
mation on cell size, membrane capacitance, and cy-
toplasm conductivity as a function of frequency. The
amplitude, opacity, and phase information can be used
to discriminate different cell populations without the use
of cell markers [61]. Recently, a label-free optofluidic
intracavity spectroscopy was developed which was inte-
grated with a microfluidic optical resonator to distin-
guish hemangiosarcoma cells from peripheral blood
monocytes [62]. The results revealed the differentiation
of HAS cells with 95% sensitivity and 98% specificity.
Cell lysate analysis Cell Lysis is a crucial step upon
which the subsequent analysis of extracted intracellular
components depends. Mechanical cell lysis system was
fabricated in early stage by using a microfluidic filter
with nano-barbs [63]. Despite the efficiency of lysing the
cells, this method failed to provide sufficient proteins for
Figure 4 Design of the microfluidic chip with a triangular chamber for a hydrodynamic single-cell docking and microperfusion culture.
A low-density cell positioning array was fabricated in a biocompatible elastomer, polydimethylsiloxane (PDMS), and bonded to a glass substrate.
The microfluidic array cytometer allowed for a gentle trapping of single live cells for prolonged periods of time. (Reproduced with permission
from Ref [58]).
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overcoming the defects, magnetic field and a centrifuga-
tion system which was used for sample homogenization
were further employed [64]. In addition, chemical lysis
method was developed based on the use of enzymes (ly-
sozymes) or detergent solutions and had the advantage
of easy-integration by dispensing the chemical from res-
ervoirs [65]. However, the lysis condition that interfered
with downstream molecular biology should be consid-
ered. Still, microfluidic electrical lysis process was devel-
oped for the analysis of subcellular materials of human
carcinoma cells [66,67]. This lysis method was character-
ized by the selective performance towards plasma mem-
brane with fast speed and simple operation while leaving
organelle membrane undamaged. Laser-induced cell lysis
techniques have begun to attract much notice which
simplify the incorporation of the lysis protocol into a
microfluidic chip. The lysis devices involved a pulsed
laser beam emitted by an optic instrument to generate
shock waves and cavitation bubbles which eventually
caused cell rupture.
Stochasticity and complexity in gene expression, protein
or metabolite levels contribute to cell-cell variations.Ideally, the relationship between the cellular heterogeneity
and cell behavior, which is key to understanding the devel-
opment, progression, and treatment of cancers should be
elucidated at the single-cell level [68]. Substantial develop-
ments have been made currently to integrate different
protocols on microfluidic platform for single cell analysis.
In the analysis of DNA patterns in single cells, a droplet-
based microfluidic platform coupled DNA purification
with sequencing of multiple gene targets was used [69].
The system enabled detailed studies of mutation co-
occurrence and synergy during carcinogenesis. Similarly, a
PCR-slide microfluidic system was presented with the re-
striction enzyme-based single-cell methylation assay [70].
A microfluidic reverse transcription-PCR chip was also
utilized to isolate mRNA templates by using beads coated
with poly-T nucleotides, as well as to synthesize cDNA
from individual cells [71]. More recently, a microfluidic
RT-qPCR device was designed capable of performing
high-precision measurements of gene transcription as well
as single nucleotide variant detection in single cancer cells
[72]. The device incorporated all steps of single-cell pro-
cessing, including cell capture, cell lysis, reverse transcrip-
tion, and quantitative PCR. For quantitative measurement
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reported for proteomic analysis of multiple oncogenic sig-
naling proteins of clinical brain tumor specimens [73].
The striking intertumoral and intratumoral heterogeneity
characteristic were revealed which further confirmed sto-
chasticity in protein levels can contribute to cell-cell varia-
tions. Notably, a microfluidic system integrated on-chip
CE was presented for both protein analysis and whole gen-
ome amplification (WGA) [74]. This technology provided
new clues for studying protein profiles of samples and
simultaneously accessing genomic information based on
WGA.
Conclusions and future trends
Microfluidic devices provide numerous advantages over
the traditional macroscale methods and slowly emerge as
new platforms in a wide range of researches in clinical on-
cology. At molecular level, the analysis methods of gene
biomarkers including gene mutations, cancer-related
methylation, and other alterations were firstly introduced
which included microfluidic chip based CAE and PCR.
Protein biomarker analysis were then reviewed which
mainly focused on the interface of microfluidics with IHC,
ELISA, and MS. At cellular level, different microfluidic
based methods were extensively employed which include
cell sorting, cell culture and unique manipulation on
isolated single cancer cells. These were, thus, particularly
attractive for the clinical and diagnostic laboratories,
allowing rapid analysis of only small amounts of patient
derived cells. Moreover, the reconstruction of cancer
microenvironment on chip provided new vistas for inte-
grated cancer cytomics in clinical diagnostics and drug
screening routines.
Regardless of the advancement in the field of micofluidic
system, this system remains in its infancy and still has sev-
eral disadvantages, such as (1) the complicated fabrication
processes, for example, the use of valves and pumps to
fabricate large arrays of microchannels often require ex-
perimental setups and equipment not readily available in
most labs; (2) the suitable interfaces for fluid transfer into,
within, and out of the microfluidic chip may not be en-
tirely satisfactory especially for portable and field-use sys-
tems; (3) the commonly used PMDS for fabricating the
microfluidic device present with hydrophobicity and pro-
pensity for protein absorption, which may disturb the bio-
assay results; (4) electrokinetics methods driving fluid flow
in microchannels suffer from the limitations of buffers in-
compatibility, electrolytic bubbles formation, evaporation
of solvent and electrophoretic demixing due to different
electrophoretic mobility; (5) the use of microfluidic sys-
tems often requires expertise which is not the part of
training for the life science professionals.
Several of the issues described above has raised a
recurring theme throughout extensive applications ofmicrofluidics that device integration for true on-chip
functionality without requiring cumbersome and costly
external ancillary equipment such as power supplies, ca-
pillary pumps, lasers, and mass spectrometers can be
practically used and more widely adopted in a variety of
laboratory, or commercial settings. These tests afforded
by microfluidic-based lab-on-a-chip devices can be ad-
ministered at a patient’s locale and even by the patient
himself, offering not only convenience but significantly
more rapid diagnosis than conventional lab-based testing.
In the long term, a detection system can be envisioned
that consists of an inexpensive, single-use, disposable cas-
sette in conjunction with a portable analyzer. Specially for
cancer detection, the microfluidic system will provide a
means for cancer typing and staging, defining the clear
boundaries of tumor mass, monitoring disease progression
and recurrence, assessing the effectiveness of therapies,
and detecting drug resistance. A more immediate and
achievable near-term goal is perhaps the seamlessly inter-
facing of microfluidic devices with conventional benchtop
laboratory processes through modular “plug and play”
platforms [75]. Moreover, the integration of novel mate-
rials (such as paper or thread) with low-cost fabrication
technologies will provide some of the most promising de-
velopments in POC diagnostics in the coming decade
[76]. These new approaches offer the promise of more
rapid prototyping with less investment in capital equip-
ment as well as greater flexibility in design.
Although the outlook of microfluidic technology is
promising, the journey towards this lofty goal will be an
extremely exciting and challenging one. There is a press-
ing need for a genuine collaborative and interdisciplinary
effort, spanning from fundamental academic research to
the commercial pathway towards translational biomed-
ical technology.
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